ESTUDO DIRIGIDO - OBESIDADE1 analise de textosLeia inicialmente o trecho abaixo, retirado da publicacao do National Institute of Health, dos Estados Unidos: Practical Guide to the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. A versao integral esta em: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf, mas voce tambem pode baixar da plataforma (Overweight and Obesity in Adults Practical Guide).Weight loss drugs approved by the FDA for long-term use may be useful as an adjunct to diet and physical activity for patients with a BMI 30 and without concomitant obesity-related risk factors or diseases. Drug therapy may also be useful for patients with a BMI 27 who also have concomitant obesity-related risk factors or diseases.The purpose of weight loss and weight maintenance is to reduce health risks. If weight is regained, health risks increase. A majority of patients who lose weight regain it, so the challenge to the patient and the practitioner is to maintain weight loss. Because of the tendency to regain weight after weight loss, the use of long-term medication to aid in the treatment of obesity may be indicated for carefully selected patients.There are few long-term studies that evaluate the safety or efficacy of most currently approved weight loss medications. At present, sibutramine* and orlistat are available for long-term use.Not every patient responds to drug therapy. Trials have shown that initial responders tend to continue to respond, whereas initial nonresponders are less likely to respond, even with an increase in dosage. If a patient does not lose 2 kilograms in the first 4 weeks after initiating therapy, the likelihood of long-term response is very low. This may be used to guide treatment by continuing medication for the responders or by discontinuing it for the nonresponders.If weight is lost within the initial 6 months of therapy or if weight is maintained after the initial weight loss phase, the drug may be continued. It is important to remember that the major role of these medications is to help patients comply with their diet and physical activity plans while losing weight. Medications cannot be expected to continue to be effective in weight loss or weight maintenance once the drug has been stopped.Drugs should be used only as part of a comprehensive program that includes behavior therapy, diet, and physical activity.Since obesity is a chronic disease, the short-term use of drugs is not helpful. The health professional should include drugs only in the context of a long-term treatment strategy. The risk/benefit ratio cannot be predicted at this time, since not enough long-term data (> 1 year) are available on any of the available drugs.*Quando o texto foi publicado, a sibutramina ainda nao era proibida nos EUA.1) Releia o ultimo paragrafo. O texto recomenda prescrever um medicamento antiobesidade durante algumas semanas ou meses com o objetivo de aumentar a aderencia do paciente a um programa de dieta e exercicios? Justifique.Nao. O uso dessas drogas por um curto periodo nao traz beneficios. Por isso, uma droga antiobesidade so deve ser incluida em abordagens a longo-prazo.2) Quais eram as duas unicas drogas aprovadas para uso em longo prazo em 2000